Background: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of
multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current …

Background In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of
multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current …

IN 2007, AT THE REQUEST of the International Union Against Tuberculosis and Lung
Disease (The Union), the World Health Organization (WHO) conducted an external review of …

SETTING: Two specialised multidrug-resistant tuberculosis (MDR-TB) treatment units in
Cameroon. OBJECTIVE: To assess outcome and adverse drug events with a standardised …

MORE THAN TWO DECADES AGO, the dosed ependent efficacy of fluoroquinolones in the
treatment of multidrug-resistant tuberculosis (MDR-TB) was first demonstrated in a clinical …

(Benin, Burkina-Faso, Burundi, Cameroon, Côte d'Ivoire, Central African Republic, Niger,
Democratic Republic of Congo and Rwanda), treated with a modified Bangladesh …

STANDARD TREATMENT for multidrug-resistant tuberculosis (MDR-TB) is lengthy and the
medications used are notorious for their significant, and at times irreversible toxicity. The …

By its very nature, tuberculosis (TB) is a relatively slowly progressive disease, and its
treatment is therefore prolonged. The development of the shortcourse treatment regimen …

IN THE MOST RECENT World Health Organization (WHO) guidelines on the treatment of
multidrugresistant tuberculosis (MDR-TB), the recommended duration of treatment is 20 …

SETTING: Nine countries in West and Central Africa. OBJECTIVE: To assess outcomes and
adverse drug events of a standardised 9-month treatment regimen for multidrug-resistant …